Higher Dose Nattokinase for Plaque and Cholesterol

What Is Nattokinase?

Nattokinase comes from natto, a traditional Japanese food made from fermented soybeans. This enzyme helps the body dissolve fibrin, a protein involved in clot formation.

Researchers have also linked nattokinase with lower blood pressure, milder inflammation, and better blood flow. In Japan, many people use natto or nattokinase supplements as part of a heart-healthy lifestyle.

However, most supplements use relatively low doses. Earlier human studies often used 2,000 to 4,000 “fibrinolytic units” (FU) per day. Results looked mixed and sometimes unimpressive. Patients and clinicians had a basic question.

Is nattokinase actually helpful, or are the usual doses simply too low?

Study Design

A large Chinese study followed 1,062 adults for 12 months. All had hyperlipidemia, early carotid plaque, or both. Many had values in the “borderline” or “mildly high” range.

Everyone took nattokinase daily. Most used 10,800 FU per day. A smaller comparison group used 3,600 FU per day, which essentially served as the baseline since the study did not use a zero-dose placebo.

Before and after 12 months, the team measured:

• Cholesterol panel
• Carotid intima media thickness (IMT)
• Carotid plaque area on ultrasound
• Basic liver and kidney function

They also recorded lifestyle factors, including exercise, smoking, alcohol intake, body weight, and whether people used vitamin K2 or aspirin.

Quick points

• 1,062 people followed for one full year
• Focus on cholesterol, triglycerides, and carotid plaque
• Main dose: 10,800 FU per day, taken orally

What Changed on 10,800 FU per Day

At 10,800 FU per day, nattokinase produced consistent, moderate improvements in the lipid profile. Average changes over 12 months included:

Measure	Before	After	Average change
Total cholesterol	5.65 mmol/L	4.75 mmol/L	About 16% lower
Triglycerides	1.85 mmol/L	1.56 mmol/L	About 16% lower
LDL cholesterol	3.58 mmol/L	2.93 mmol/L	About 18% lower
HDL cholesterol	1.38 mmol/L	1.60 mmol/L	About 16% higher

Most participants improved. Roughly 85 to 95% saw better numbers across the lipid panel.

The carotid ultrasound findings also changed. On average, carotid IMT fell by about 22%. Plaque area dropped by about 36%. About three quarters of participants improved their IMT. About two thirds reduced plaque area.

Quick points

• Lipids improved in the large majority of people
• LDL fell roughly 18% on average
• Carotid plaque and wall thickness decreased in many participants

Why Dose and Lifestyle Matter

A key finding stands out. The low dose of 3,600 FU per day did not work. Lipids and carotid plaque measurements stayed essentially unchanged in that group.

By contrast, 10,800 FU per day produced meaningful changes. This supports a “threshold” idea. Below a certain dose, nattokinase looks weak. Above that range, its impact becomes visible.

Lifestyle also shaped the response. People who walked more than 5,000 steps per day responded better than sedentary participants. Those with higher BMI also saw larger relative improvements, likely because they started from a higher risk baseline.

Smokers and regular alcohol users had worse numbers at baseline. Interestingly, they also showed slightly larger percentage improvements with nattokinase, again likely due to greater room for change.

Co-administration mattered as well:

Factor	Effect on nattokinase response
3,600 FU daily	No clear benefit
10,800 FU daily	Clear lipid and plaque improvement
Regular exercise	Stronger response overall
Higher BMI	Larger relative improvements
Vitamin K2	Better lipid changes, similar plaque effects
Low dose aspirin	Better lipids and more plaque regression

This pattern suggests that nattokinase works best as part of a broader cardiovascular strategy, not as a stand-alone tool.

How This Fits With Other Heart Treatments

This study followed people who chose nattokinase as a health approach rather than standard medication-based protocols. It did not directly compare nattokinase with statins, ezetimibe, or PCSK9 inhibitors.

However, the magnitude of LDL reduction looks closer to a moderate lifestyle change or low-intensity statin effect. It gives a useful tool for patients who:

• Cannot tolerate statins
• Want an additional non-prescription support layer
• Carry mild plaque or borderline lipids, as documented on testing

In a cardiometabolic clinic, nattokinase would usually fit beside, not instead of, standard therapies when those are indicated. It may support plaque stabilization, better flow, and gentler inflammatory tone.

Approach	Average LDL Reduction
Lifestyle alone	5 to 15%
Nattokinase 10,800 FU	~18%
Low-intensity statin	20 to 30%
High-intensity statin	50% or more

A Note of Caution on Bleeding Risk and Medical Supervision

Nattokinase acts on fibrin and influences clot balance. This means it can interact with the body’s natural bleeding and coagulation systems. Most people in this large study tolerated high-dose nattokinase without concerning events. However, real world use can differ. People who use blood thinners, antiplatelet drugs, or combination regimens may face higher bleeding risk when they add nattokinase.

Individuals with recent surgery, active ulcers, kidney disease, liver disease, or unexplained bruising also need careful evaluation. Medical supervision matters because nattokinase can work alongside or against other therapies. Clinicians can monitor interactions, guide dosing, and match the supplement to each patient’s cardiovascular and metabolic profile.

Patient Stories: How Nattokinase Might Look in Real Life

• Case 1 – Borderline Plaque in a Careful Walker: A 68-year-old woman has mild carotid plaque and slightly high LDL. She walks 7,000 steps daily and prefers non-prescription options. A structured plan combines nattokinase 10,800 FU, diet upgrades, and blood pressure tuning. After a year, LDL falls modestly and plaque size shrinks on repeat ultrasound.
• Case 2 – Statin Intolerance and Metabolic Risk: A 62-year-old man has muscle aches with several statins. His non-HDL remains moderately high and ultrasound shows thickened carotid walls. He starts nattokinase 10,800 FU, increases walking, and adjusts nutrition. Non-HDL drops into a safer range. Carotid IMT improves, and his overall risk profile softens.
• Case 3 – Smoker with Early Plaque: A 59-year-old smoker shows soft plaque on carotid imaging. His triglycerides and LDL sit high-normal. He agrees to serious lifestyle work, including smoking reduction, exercise, and nattokinase 10,800 FU. Over 12 months, his lipids improve, plaque regresses slightly, and he moves closer to quitting smoking.
• Case 4 – Higher BMI and Silent Atherosclerosis: A 66-year-old woman with elevated BMI and mild sleep apnea has silent plaque on imaging. She uses nattokinase 10,800 FU, improves sleep, and receives structured nutrition support. Her triglycerides drop, HDL rises, and plaque burden decreases on follow-up testing.

Frequently Asked Questions About Nattokinase

1. Can vitamins remove plaque from arteries?

No vitamin has been proven to reliably remove established arterial plaque.

Atherosclerosis develops through lipid retention, inflammation, endothelial injury, and metabolic stress. True plaque regression usually requires meaningful LDL and ApoB reduction, blood pressure optimization, and metabolic correction.

Certain nutrients such as omega-3 fatty acids or vitamin K2 may support vascular health. However, they do not consistently dissolve plaque. Imaging and structured cardiometabolic management remain the foundation.

2. What is the best nattokinase dosage for plaque removal?

In the 1,062 participant study discussed above, 10,800 FU per day showed measurable improvements in carotid plaque area and intima-media thickness over 12 months.

Lower doses such as 2,000 to 3,600 FU per day did not produce meaningful plaque change.

This suggests a threshold effect. Below a certain range, nattokinase appears weak. At 10,800 FU daily, plaque regression became measurable in many participants.

3. How much nattokinase should I take for cholesterol?

In the same study, 10,800 FU per day produced average improvements of:

• LDL cholesterol decreased by about 18%
• Triglycerides decreased by about 16%
• Total cholesterol decreased by about 16%
• HDL cholesterol increased by about 16%

Lower doses did not significantly change lipid values. As always, dosing decisions should account for bleeding risk, medications, and overall cardiovascular profile.

4. Is 10,800 FU of nattokinase safe?

In the 12 month study, most participants tolerated 10,800 FU daily without meaningful changes in liver or kidney function.

However, nattokinase influences clot balance because it acts on fibrin and thrombin pathways. Individuals taking anticoagulants, antiplatelet therapy, or combination regimens require careful evaluation before use.

Safety depends on the full clinical picture, not the supplement alone.

5. Which Japanese food contains nattokinase?

Natto, a traditional Japanese fermented soybean dish, naturally contains nattokinase.

Epidemiologic studies in Japan associate natto intake with lower cardiovascular mortality. However, supplement doses used in plaque studies often exceed what typical dietary natto provides.

Dietary natto supports cardiovascular health, but concentrated supplement dosing differs from food intake.

6. Can nattokinase completely clear plaque?

No evidence shows that nattokinase completely eliminates advanced plaque.

In the study above, plaque area decreased by about 36% on average in many participants. That represents regression, not full removal. Risk reduction depends more on stabilization, lipid control, and inflammation reduction than complete disappearance.

7. Is nattokinase better than a statin?

This study did not directly compare nattokinase with statins.

An average 18% LDL reduction resembles low intensity statin therapy or a strong lifestyle intervention. Moderate or high intensity statins typically reduce LDL by 30 to 50% or more.

In clinical practice, nattokinase may serve as an adjunct in selected patients. It does not replace indicated statin therapy in high risk individuals.

Practical Takeaways for Patients

Nattokinase from this study suggests several practical messages.

• Dose matters. Typical low doses like 2,000 to 3,600 FU may be too weak.
• Higher dose use at 10,800 FU per day can improve lipids and plaque.
• Movement, weight pattern, smoking, and alcohol habits still shape outcomes.
• Vitamin K2 and low dose aspirin may enhance effects in selected patients.
• Liver and kidney tests stayed stable in this large group.

As always, the smart strategy involves a broader context. Imaging, advanced lipid markers, blood pressure, insulin resistance, sleep quality, and inflammation all interact. Nattokinase can support the overall plan when used thoughtfully.

At our practice in Montgomery County, Maryland, and through virtual care, we use a comprehensive and thoughtful strategy that supports metabolic health from multiple angles. This approach improves long term outcomes without adding new risks.